Filtered By:
Cancer: Myeloma

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 122 results found since Jan 2013.

Notch Increased Vitronection Adhesion Protects myeloma cells from drug induced Apoptosis.
This study first connected Notch signaling, VTN adhesion and drug resistance together. Therefore, blocking αvβ5 receptor with antibody or knock down approach would be a novel promising strategy to treat MM. PMID: 26494298 [PubMed - as supplied by publisher]
Source: Biochemical and Biophysical Research communications - October 19, 2015 Category: Biochemistry Authors: Ding Y, Shen Y Tags: Biochem Biophys Res Commun Source Type: research

Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy.
Abstract Bortezomib (BTZ) is a frequently used chemotherapeutic drug for the treatment of refractory multiple myeloma and hematological neoplasms. The mechanism by which the administration of BTZ leads to painful peripheral neuropathy remains unclear. In present study, we found that application of BTZ at 0.4 mg/kg for consecutive 5 days significantly increased the expression of CCL2 in DRG, and intrathecal administration of neutralizing antibody against CCL2 inhibited the mechanical allodynia induced by BTZ. We also found an increased expression of c-Jun in DRG, and that inhibition of c-Jun signaling prevented the...
Source: Brain, Behavior, and Immunity - November 7, 2015 Category: Neurology Authors: Liu C, Luan S, OuYang H, Huang Z, Wu S, Ma C, Wei J, Xin W Tags: Brain Behav Immun Source Type: research

Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy
Publication date: Available online 10 November 2015 Source:Brain, Behavior, and Immunity Author(s): Cuicui Liu, Shuo Luan, Handong OuYang, Zhenzhen Huang, Shaoling Wu, Chao Ma, Jiayou Wei, Wenjun Xin Bortezomib (BTZ) is a frequently used chemotherapeutic drug for the treatment of refractory multiple myeloma and hematological neoplasms. The mechanism by which the administration of BTZ leads to painful peripheral neuropathy remains unclear. In present study, we found that application of BTZ at 0.4 mg/kg for consecutive 5 days significantly increased the expression of CCL2 in DRG, and intrathecal administration of n...
Source: Brain, Behavior, and Immunity - November 13, 2015 Category: Neurology Source Type: research

Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.
Authors: Lin L, Yan F, Zhao D, Lv M, Liang X, Dai H, Qin X, Zhang Y, Hao J, Sun X, Yin Y, Huang X, Zhang J, Lu J, Ge Q Abstract Reelin is an extracellular matrix (ECM) protein that is essential for neuron migration and positioning. The expression of reelin in multiple myeloma (MM) cells and its association with cell adhesion and survival were investigated. Overexpression, siRNA knockdown, and the addition of recombinant protein of reelin were used to examine the function of reelin in MM cells. Clinically, high expression of reelin was negatively associated with progression-free survival and overall survival. Functi...
Source: Oncotarget - February 9, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Che-1 gene silencing by inhibiting mutant p53 expression.
In this study, we aimed to investigate the effects and specific mechanism of Che-1 in the regulation of osteosarcoma (OS) cell growth. We found that Che-1 is highly expressed in several kinds of OS cells compared with osteoblast hFOB1.19 cells. MTT and flow cytometry assays showed that Che-1 depletion by siRNA markedly suppressed MG-63 and U2OS cell proliferation and promoted apoptosis. The chromatin immunoprecipitation (ChIP) assay verified the presence of Che-1 on the p53 promoter in MG-63 and U2OS cells carrying mutant p53. Further studies showed that Che-1 depletion inhibited mutant p53 expression. Notably, our study s...
Source: Biochemical and Biophysical Research communications - March 20, 2016 Category: Biochemistry Authors: Liu M, Wang D, Li N Tags: Biochem Biophys Res Commun Source Type: research

Preparation of Antispermidine/Spermine-N1-Acetyltransferase Monoclonal Antibodies.
Authors: Chen Y, Zhang C Abstract Spermidine/spermine N1-acetyltransferase (SSAT) is a catabolic regulator of polyamines, ubiquitous molecules essential for cell proliferation and differentiation. Anti-SSAT antibodies (monoclonal antibodies [mAbs]) of high titer were prepared by immunizing BALB/c mice with multifocal intradermal injections and by fusing high-titer antibody-producing spleen cells with myeloma cells of SP2/0 origin. Four mAbs were selected for further characterization as classes and subclasses. Antibodies were produced by these three clones with high affinities ranging from 10(9) to 10(11) M(-1). The...
Source: Monoclonal Antibodies in Immunodiagnosis and Immunotherapy - May 28, 2016 Category: Microbiology Tags: Monoclon Antib Immunodiagn Immunother Source Type: research

Metformin elicits antitumor effects and downregulates the histone methyltransferase multiple myeloma SET domain (MMSET) in prostate cancer cells
CONCLUSIONSThese data suggest MMSET may play a role in the inhibitory effect of metformin on PCa and could serve as a potential novel therapeutic target for PCa. Prostate © 2016 Wiley Periodicals, Inc.
Source: The Prostate - July 11, 2016 Category: Urology & Nephrology Authors: Nicole M. A. White‐Al Habeeb, Julia Garcia, Neil Fleshner, Bharati Bapat Tags: Original Article Source Type: research

CSTMP induces apoptosis and mitochondrial dysfunction in human myeloma RPMI8226 cells via CHOP-dependent endoplasmic reticulum stress.
CONCLUSIONS: Our results indicated that CSTMP could induce apoptosis and mitochondrial dysfunction in RPMI8226 cells via CHOP-dependent ER stress. PMID: 27490778 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 31, 2016 Category: Drugs & Pharmacology Authors: Sun X, Liao W, Wang J, Wang P, Gao H, Wang M, Xu C, Zhong Y, Ding Y Tags: Biomed Pharmacother Source Type: research

Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming.
Authors: Riz I, Hawley TS, Marsal JW, Hawley RG Abstract Multiple Myeloma (MM) is a B-cell malignancy characterized by the accumulation of clonal plasma cells in the bone marrow, with drug resistance being a major cause of therapeutic failure. We established a carfilzomib-resistant derivative of the LP-1 MM cell line (LP-1/Cfz) and found that the transcription factor NF-E2 p45-related factor 2 (Nrf2; gene symbol NFE2L2) contributes to carfilzomib resistance. The mechanism of Nrf2 activation involved enhanced translation of Nrf2 as well as its positive regulator, the autophagy receptor sequestosome 1 (SQSTM1)/p62. T...
Source: Oncotarget - September 15, 2016 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in vivo in a mouse xenogtraft model
Multiple myeloma (MM) is an incurable malignancy by the presently known therapies. TRAIL is a promising anticancer agent that virtually not shows any toxicity to normal cells. We have recently carried out clinical trials with a human circularly permuted TRAIL, CPT, against MM saw a partial response in approximate 20 – 30% of patients. In the current study, we investigated the cause of CPT resistance and revealed that the majority of the MM patients express elevated levels of c-FLIP. Knockdown of c-FLIP expression by siRNA alone was sufficient to increase CPT-mediated apoptosis in a CPT-resistant human MM cell line U266.
Source: Cancer Letters - December 17, 2016 Category: Cancer & Oncology Authors: Yin Wu, Marco Giaisi, Rebecca K öhler, Dr. Wen-Ming Chen, Peter H. Krammer, Dr. Min Li-Weber Tags: Original Articles Source Type: research

Rocaglamide breaks TRAIL-resistance in human multiple myeloma and acute T-cell leukemia in  vivo in a mouse xenogtraft model
Multiple myeloma (MM) is an incurable malignancy by the presently known therapies. TRAIL is a promising anticancer agent that virtually not shows any toxicity to normal cells. We have recently carried out clinical trials with a human circularly permuted TRAIL, CPT, against MM saw a partial response in approximate 20 –30% of patients. In the current study, we investigated the cause of CPT resistance and revealed that the majority of the MM patients express elevated levels of c-FLIP. Knockdown of c-FLIP expression by siRNA alone was sufficient to increase CPT-mediated apoptosis in a CPT-resistant human MM cell line U266.
Source: Cancer Letters - December 17, 2016 Category: Cancer & Oncology Authors: Yin Wu, Marco Giaisi, Rebecca K öhler, Wen-Ming Chen, Peter H. Krammer, Min Li-Weber Tags: Original Article Source Type: research

Molecules, Vol. 22, Pages 276: Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase
Ginkgolic acid C 17:1 (GAC 17:1) extracted from Ginkgo biloba leaves, has been previously reported to exhibit diverse antitumor effect(s) through modulation of several molecular targets in tumor cells, however the detailed mechanism(s) of its actions still remains to be elucidated. Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor that regulates various critical functions involved in progression of diverse hematological malignancies, including multiple myeloma, therefore attenuating STAT3 activation may have a potential in cancer therapy. We determined the anti-tumor mechanism ...
Source: Molecules - February 12, 2017 Category: Chemistry Authors: Seung Baek Jong Lee Chulwon Kim Jeong-Hyeon Ko Seung-Hee Ryu Seok-Geun Lee Woong Yang Jae-Young Um Arunachalam Chinnathambi Sulaiman Alharbi Gautam Sethi Kwang Ahn Tags: Article Source Type: research

Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
CONCLUSIONS: Our preclinical studies provide the framework for clinical evaluation of USP1 inhibitors, alone or in combination, as a potential novel MM therapy. PMID: 28270494 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 6, 2017 Category: Cancer & Oncology Authors: Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC Tags: Clin Cancer Res Source Type: research

Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6 Signal Transduction
The pathogenesis of multiple myeloma (MM) has not yet been fully elucidated. Our microarray analysis and immunohistochemistry revealed significant up-regulation of growth arrest-specific gene 6 (Gas6), a vitamin K-dependent protein with a structural homology with protein S, in bone marrow (BM) cells of MM patients. ELISA showed that the serum levels of soluble Gas6 were significantly increased in the MM patients when compared with healthy controls. Gas6 was overexpressed in the human CD138-positive MM cell line RPMI-8226. Exogenous Gas6 suppressed apoptosis induced by serum deprivation and enhanced cell proliferation of th...
Source: Journal of Biological Chemistry - March 9, 2017 Category: Chemistry Authors: Miki Furukawa, Hiroshi Ohkawara, Kazuei Ogawa, Kazuhiko Ikeda, Koki Ueda, Akiko Shichishima-Nakamura, Emi Ito, Jun-ichi Imai, Yuka Yanagisawa, Reiko Honma, Shinya Watanabe, Satoshi Waguri, Takayuki Ikezoe, Yasuchika Takeishi Tags: Cell Biology Source Type: research

Long Non-coding RNA CRNDE Promotes Multiple Myeloma Cell Growth By Suppressing MiR-451.
In this study, we found that the CRNDE expression level, in MM sample and cell lines, is higher than control detected by real-time qPCR, which is also closely related to tumor progression and poor survival in MM patients. Afterwards, knockdown of CRNDE significantly inhibits the proliferative vitality of MM cells (U266 and RPMI8226), meanwhile, induces cell cycle arrest in G0/G1 phase and apoptosis-promoting. After being transfected with siRNA, miR-451 expression observably increases. Bioinformatics analysis and luciferase assay reveal the interaction complementary bonding between CRNDE and miR-451. Pearson's correlation s...
Source: Oncology Research - March 10, 2017 Category: Cancer & Oncology Tags: Oncol Res Source Type: research